Autopsy report · NCT02177825

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

“Slow accrual 5 patients out of 25 expected. Primary objectives could not be met without recruiting more patients.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 9 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

St. Justine's Hospital

Sponsor type

University, hospital or other

Conditions

Plexiform Neurofibromas

Interventions

Imatinib Mesylate

Participants

5

Sites

1

Countries

Canada

Trials that died the same way

• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
  “Due to slow accrual of patients” (71% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (67% match in meaning)
• Efficacy of Acetaminophen in Posterior Fossa Surgery
  “not enough patients meeting criteria” (66% match in meaning)
• Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
  “Slow accrual and changes in clinical practice” (65% match in meaning)
• Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
  “Unable to accrue patients at a reasonable rate” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.